TP53 and myelodysplastic syndrome: Moreover, the combination of APR-246 and azacitidine is under investigation as maintenance therapy after allogeneic HSCT in AML and MDS patients with TP53 mutation (NCT03931291), and as part of a triple therapy with venetoclax in a phase 1 study in patients with TP53-mutated hematologic malignancies (NCT04214860).